If you believe some on here then it looks like Mesoblast have pulled the wool over the FDA's eyes (again) joke joyce .... lol
I am sure we will see some on repeat today telling us that this is no big deal .... it is a big deal and it will provide leverage in the CLBP partnership negotiations - remember the CLBP trial is scheduled to start by EOFY ...
...... perhaps Mesoblast were waiting for this RMAT designation prior to finalising a partnership and starting the CLBP trial ? Could this be why Mesoblast pushed the time lines out to FH CY 2023 ? Either way this is a positive announcement no matter what the naysaying cult say today
GLTAH
Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP, page-15
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.060(5.83%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.10 | $1.03 | $4.925M | 4.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7260 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 67541 | 7 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |